Ultragenyx Pharmaceutical Inc.
RARE
$35.11
-$0.87-2.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -15.52% | 18.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -15.52% | 18.20% | |||
| Cost of Revenue | -72.80% | 3,300.21% | |||
| Gross Profit | 89.97% | -564.14% | |||
| SG&A Expenses | 6.43% | 2.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.71% | 5.77% | |||
| Operating Income | -16.90% | 7.36% | |||
| Income Before Tax | -12.27% | -0.14% | |||
| Income Tax Expenses | 6,994.74% | -106.27% | |||
| Earnings from Continuing Operations | -13.27% | 0.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.27% | 0.10% | |||
| EBIT | -16.90% | 7.36% | |||
| EBITDA | -18.33% | 8.14% | |||
| EPS Basic | -12.55% | 0.29% | |||
| Normalized Basic EPS | -12.75% | 1.71% | |||
| EPS Diluted | -12.55% | 0.29% | |||
| Normalized Diluted EPS | -12.75% | 1.71% | |||
| Average Basic Shares Outstanding | 0.63% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.63% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||